Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canocapavir plus entecavir versus entecavir alone in entecavir-treated chronic hepatitis B
CTR20221976Phase 2Completed
- Sponsor
- Zhimeng Biopharma
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Canocapavir in Chronic Hepatitis B (CHB), sponsored by Zhimeng Biopharma. Primary endpoints: Complete virologic response at Week 24 and Safety during first 24 weeks. Started Dec 2022; status: completed.
02
Drugs
Canocapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20221976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221976.